Håkon Reikvam, Kimberley Joanne Hatfield, Hanne Fredly, Ina Nepstad, Knut Anders Mosevoll, Øystein Bruserud
European Cytokine Network, Vol.23, No.4, pp. 140-153, 2012, DOI:10.1684/ecn.2012.0322
Abstract Acute myeloid leukemia (AML) is characterized by bone marrow accumulation of immature leukemic
blast cells. Conventional AML treatment includes induction chemotherapy to achieve disease control, followed by
consolidation therapy with conventional chemotherapy or allogeneic/autologous stem cell transplantation (allo/autoSCT)
to eradicate residual disease. Even younger patients receiving the most intensive treatment have a median,
long-term, AML-free survival of only 45-50%, highlighting the need for new treatment strategies. The important
role of the bone marrow cytokine network during disease development and treatment is suggested by several
observations, including: (i) the increased microvascular density (MVD) in leukemic bone… More >